Cristin-resultat-ID: 2045102
Sist endret: 6. januar 2023, 11:31
NVI-rapporteringsår: 2022
Resultat
Vitenskapelig oversiktsartikkel/review
2022

A state of the art in analytical quality-by-design and perspectives in characterization of nano-enabled medicinal products

Bidragsytere:
  • Thierry Bastogne
  • Fanny Caputo
  • Adriele Prina-Mello
  • Sven Even F. Borgos og
  • Muriel Barberi-Heyob

Tidsskrift

Journal of Pharmaceutical and Biomedical Analysis
ISSN 0731-7085
e-ISSN 1873-264X
NVI-nivå 1

Om resultatet

Vitenskapelig oversiktsartikkel/review
Publiseringsår: 2022
Publisert online: 2022
Trykket: 2022
Volum: 219
Sider: 1 - 12
Artikkelnummer: 114911

Importkilder

Scopus-ID: 2-s2.0-85133248325

Beskrivelse Beskrivelse

Tittel

A state of the art in analytical quality-by-design and perspectives in characterization of nano-enabled medicinal products

Sammendrag

Quality-by-Design (QbD) guidance is a risk-based and proactive approach to drug development proposed in the early 2000s and now widely used in the pharmaceutical field in compliance with the ICH Q8-Q11 guidelines. Analytical Quality by Design (AQbD), introduced in 2010, is the adaptation of the QbD paradigm for the development of analytical methods. AQbD aims at optimizing the accuracy and robustness of analysis results by identifying and controlling critical analytical variables and method parameters over the entire protocol, including biological sample preparation, measurement technology and statistical analysis. Nevertheless, much remains to be done for a clear understanding and an efficient implementation of this new paradigm in practice. The first objective of this review is to propose a global clarification of the Analytical Quality by Design approach by reviewing its terminology and steps and by clarifying its relationships with the well-established QbD paradigm and ICH guidelines. Two new templates of documents have been proposed: a form designed for the definition of the analytical target profile and a connection matrix between expected metrological properties and analytical attributes. Finally, the open challenges in the characterization of nano-enabled medicinal products are examined from the AQbD angle.

Bidragsytere

Thierry Bastogne

  • Tilknyttet:
    Forfatter
    ved Université de Lorraine
  • Tilknyttet:
    Forfatter
    ved Frankrike

Fanny Caputo

  • Tilknyttet:
    Forfatter
    ved Bioteknologi og nanomedisin ved SINTEF AS

Adriele Prina-Mello

  • Tilknyttet:
    Forfatter
    ved The University of Dublin, Trinity College

Sven Even F. Borgos

  • Tilknyttet:
    Forfatter
    ved Bioteknologi og nanomedisin ved SINTEF AS

Muriel Barberi-Heyob

  • Tilknyttet:
    Forfatter
    ved Université de Lorraine
1 - 5 av 5